New LDL cholesterol target ahead?

03/4/2013 | Nature (free content)

For the first time in a decade, the U.S. National Heart, Lung and Blood Institute is expected to reconsider its clinical guidelines for LDL cholesterol. Statins have been shown to lower the risk of cardiovascular events, but it has not been proven that reducing LDL with other pharmaceuticals has an impact, some cardiologists say. "We can't just assume that modifying the risk factor is modifying risk," says Harlan Krumholz of Yale University.

View Full Article in:

Nature (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY